Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranitidine does not affect psoriasis: a multicenter, double-blind, placebo-controlled study

I M Zonneveld1, M M Meinardi, T Karlsmark

  • 1Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands.

Journal of the American Academy of Dermatology
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment.

The British journal of dermatology·2016
Same author

Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years.

The British journal of dermatology·2016
Same author

Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015
Same author

The skin immune system Its cellular constituents and their interactions.

Immunology today·2014
Same author

Provoking factors, including chemicals, in Dutch patients with vitiligo.

The British journal of dermatology·2012
Same journal

Localized radiation therapy provides more durable disease control than topical steroids in stage IA mycosis fungoides.

Journal of the American Academy of Dermatology·2026
Same journal

Atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated sarcoma: Updates on diagnosis, management, and surveillance.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Li et al., "Comment on Nie et al. (2026) 'Suicidality Reports in Acne Patients Treated with Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data'".

Journal of the American Academy of Dermatology·2026
Same journal

Treatment Utilization Patterns in Cutaneous Lupus Erythematosus: A Single-Center Retrospective Analysis.

Journal of the American Academy of Dermatology·2026
Same journal

Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy.

Journal of the American Academy of Dermatology·2026
Same journal

Incise parallel, section perpendicular to the dermatoglyphs for diagnosis of acral melanocytic lesions-A comment on Thakker et al.

Journal of the American Academy of Dermatology·2026
See all related articles

Ranitidine was studied for psoriasis treatment in a large clinical trial. Results showed ranitidine did not significantly improve psoriasis symptoms compared to placebo.

Area of Science:

  • Dermatology
  • Clinical Pharmacology

Background:

  • Open studies suggested ranitidine may benefit psoriasis patients.
  • Ranitidine was reported to be well-tolerated in previous research.

Purpose of the Study:

  • To evaluate ranitidine's efficacy for psoriasis.
  • A 24-week, multicenter, double-blind, placebo-controlled study was conducted.
  • 201 patients with psoriasis participated in the trial.

Main Methods:

  • Patients with moderate to severe psoriasis were enrolled after stopping other therapies.
  • Participants received ranitidine (150 mg or 300 mg twice daily) or placebo.
  • Psoriasis Area and Severity Index (PASI) scores were assessed throughout the 24-week study.

Main Results:

Related Experiment Videos

  • Success rates (70% PASI reduction) at 24 weeks were 11% (300 mg ranitidine), 5% (600 mg ranitidine), and 12% (placebo).
  • No statistically significant differences in treatment outcomes were observed between ranitidine and placebo groups.
  • Ranitidine demonstrated no discernible effect on psoriasis severity.

Conclusions:

  • This study provides robust evidence against ranitidine's effectiveness in treating psoriasis.
  • Ranitidine does not appear to impact the skin condition in psoriasis patients.